vs

Side-by-side financial comparison of LEXICON PHARMACEUTICALS, INC. (LXRX) and MOVING iMAGE TECHNOLOGIES INC. (MITQ). Click either name above to swap in a different company.

LEXICON PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($5.5M vs $3.8M, roughly 1.4× MOVING iMAGE TECHNOLOGIES INC.). MOVING iMAGE TECHNOLOGIES INC. runs the higher net margin — -10.2% vs -282.7%, a 272.5% gap on every dollar of revenue. On growth, LEXICON PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (254.4% vs 10.2%). Over the past eight quarters, LEXICON PHARMACEUTICALS, INC.'s revenue compounded faster (124.2% CAGR vs 7.8%).

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its patented mouse gene knockout technology and extensive in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 1...

Silicon Image Inc. was an American fabless semiconductor company based in Hillsboro, Oregon, and active from 1995 to 2015. The company designed circuits for mobile phones, consumer electronics and personal computers (PCs). It also manufactured wireless and wired connectivity products used for high-definition content. The company's semiconductor and IP products were deployed by manufacturers in devices such as smartphones, tablets, digital televisions (DTVs), and other consumer electronics, as...

LXRX vs MITQ — Head-to-Head

Bigger by revenue
LXRX
LXRX
1.4× larger
LXRX
$5.5M
$3.8M
MITQ
Growing faster (revenue YoY)
LXRX
LXRX
+244.2% gap
LXRX
254.4%
10.2%
MITQ
Higher net margin
MITQ
MITQ
272.5% more per $
MITQ
-10.2%
-282.7%
LXRX
Faster 2-yr revenue CAGR
LXRX
LXRX
Annualised
LXRX
124.2%
7.8%
MITQ

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
LXRX
LXRX
MITQ
MITQ
Revenue
$5.5M
$3.8M
Net Profit
$-15.5M
$-388.0K
Gross Margin
96.3%
30.7%
Operating Margin
-269.1%
-10.8%
Net Margin
-282.7%
-10.2%
Revenue YoY
254.4%
10.2%
Net Profit YoY
54.0%
26.4%
EPS (diluted)
$-0.04
$-0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LXRX
LXRX
MITQ
MITQ
Q4 25
$5.5M
$3.8M
Q3 25
$14.2M
$5.6M
Q2 25
$28.9M
Q1 25
$1.3M
$3.6M
Q4 24
$1.6M
$3.4M
Q3 24
$1.7M
$5.3M
Q2 24
$1.6M
$6.3M
Q1 24
$1.1M
$3.9M
Net Profit
LXRX
LXRX
MITQ
MITQ
Q4 25
$-15.5M
$-388.0K
Q3 25
$-12.8M
$509.0K
Q2 25
$3.3M
Q1 25
$-25.3M
$-240.0K
Q4 24
$-527.0K
Q3 24
$-64.8M
$-25.0K
Q2 24
$-53.4M
$-416.0K
Q1 24
$-48.4M
$-601.0K
Gross Margin
LXRX
LXRX
MITQ
MITQ
Q4 25
96.3%
30.7%
Q3 25
99.9%
30.0%
Q2 25
99.9%
Q1 25
97.6%
29.8%
Q4 24
77.5%
27.2%
Q3 24
95.9%
26.1%
Q2 24
89.7%
22.5%
Q1 24
97.2%
17.4%
Operating Margin
LXRX
LXRX
MITQ
MITQ
Q4 25
-269.1%
-10.8%
Q3 25
-85.9%
6.3%
Q2 25
12.9%
Q1 25
-2034.8%
-7.6%
Q4 24
-16.3%
Q3 24
-3658.4%
-1.3%
Q2 24
-3423.3%
-7.3%
Q1 24
-4147.6%
-16.7%
Net Margin
LXRX
LXRX
MITQ
MITQ
Q4 25
-282.7%
-10.2%
Q3 25
-90.0%
9.1%
Q2 25
11.3%
Q1 25
-2004.4%
-6.7%
Q4 24
-15.3%
Q3 24
-3722.6%
-0.5%
Q2 24
-3304.2%
-6.6%
Q1 24
-4427.9%
-15.4%
EPS (diluted)
LXRX
LXRX
MITQ
MITQ
Q4 25
$-0.04
$-0.04
Q3 25
$-0.04
$0.05
Q2 25
$0.01
Q1 25
$-0.07
$-0.02
Q4 24
$-0.05
Q3 24
$-0.18
$0.00
Q2 24
$-0.17
$-0.04
Q1 24
$-0.20
$-0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LXRX
LXRX
MITQ
MITQ
Cash + ST InvestmentsLiquidity on hand
$96.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$107.5M
$5.0M
Total Assets
$185.0M
$9.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LXRX
LXRX
MITQ
MITQ
Q4 25
$96.2M
Q3 25
$116.0M
Q2 25
$139.0M
Q1 25
$194.8M
Q4 24
$238.0M
Q3 24
$258.4M
Q2 24
$310.0M
Q1 24
$355.6M
Stockholders' Equity
LXRX
LXRX
MITQ
MITQ
Q4 25
$107.5M
$5.0M
Q3 25
$120.2M
$5.4M
Q2 25
$129.4M
Q1 25
$123.0M
$5.0M
Q4 24
$145.9M
$5.2M
Q3 24
$178.5M
$5.7M
Q2 24
$240.0M
$5.7M
Q1 24
$288.9M
$6.3M
Total Assets
LXRX
LXRX
MITQ
MITQ
Q4 25
$185.0M
$9.5M
Q3 25
$205.9M
$11.3M
Q2 25
$225.6M
Q1 25
$297.7M
$11.2M
Q4 24
$298.4M
$10.0M
Q3 24
$321.1M
$10.7M
Q2 24
$373.4M
$10.5M
Q1 24
$417.2M
$12.7M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LXRX
LXRX
MITQ
MITQ
Operating Cash FlowLast quarter
$-17.2M
$-1.6M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LXRX
LXRX
MITQ
MITQ
Q4 25
$-17.2M
$-1.6M
Q3 25
$-23.8M
$-167.0K
Q2 25
$17.0M
Q1 25
$-43.8M
$53.0K
Q4 24
$-178.8M
$70.0K
Q3 24
$-53.6M
$-32.0K
Q2 24
$-48.5M
$-472.0K
Q1 24
$-55.1M
$1.0M
Free Cash Flow
LXRX
LXRX
MITQ
MITQ
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$-179.8M
Q3 24
$-53.9M
Q2 24
$-48.8M
Q1 24
FCF Margin
LXRX
LXRX
MITQ
MITQ
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-11600.7%
Q3 24
-3097.4%
Q2 24
-3017.3%
Q1 24
Capex Intensity
LXRX
LXRX
MITQ
MITQ
Q4 25
Q3 25
0.0%
Q2 25
Q1 25
Q4 24
66.5%
Q3 24
17.6%
Q2 24
15.5%
0.0%
Q1 24
0.0%
0.0%
Cash Conversion
LXRX
LXRX
MITQ
MITQ
Q4 25
Q3 25
-0.33×
Q2 25
5.23×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons